InMed Pharmaceuticals(US:INM) Benzinga·2025-11-20 07:28Core Insights - InMed Pharmaceuticals Inc. shares experienced a significant increase of 21.98% in after-hours trading, reaching a price of $1.50 after closing at $1.23, which was a decline of 15.75% during the regular session [1]. Group 1: Study Milestones - The company announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer's disease candidate INM-901, marking the first preclinical study to administer the oral formulation in large animals [2]. - The studies demonstrated strong bioavailability in in vivo models over a seven-day period, achieving therapeutic systemic exposure levels for INM-901 [3]. Group 2: Regulatory Path Forward - InMed has completed additional chemistry, manufacturing, and controls development to scale production for Investigational New Drug-enabling studies. The company plans to conduct dose-ranging studies, a pre-IND meeting with the FDA, and Good Laboratory Practice-enabling studies to support its IND submission [4]. Group 3: Financial Position and Stock Performance - As of September 30, the company reported $9.3 million in cash, sufficient to fund operations into the fourth quarter of 2026. However, InMed's stock has declined by 74.38% year-to-date, trading within a 52-week range of $1.23 to $8.27, with a market capitalization of $3.45 million [5].